Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Advances in GvHD and maintenance following transplant

Katie Maurer • 5 Feb 2021
TCT 2021
General

Katie Maurer, MD, PhD, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, explores exciting updates in therapies for steroid-refractory graft-versus-host disease (GvHD), as well as the use of maintenance therapies following transplantation. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Katie Maurer

1:38
Learnings of COVID-19 on transplant and cellular therapies
Katie Maurer • 5 Feb 2021
4:33
Impact of COVID-19 on HSCT and cellular therapies in the US
Katie Maurer • 2 Feb 2021

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals